When close to half the companies in India have price-to-earnings ratios (or “P/E’s”) below 33x, you may consider Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) as a stock to potentially avoid with its 41x P/E ratio. However, the P/E might be high for a reason and it requires further investigation to determine if it’s justified. There hasn’t been much to differentiate Sun Pharmaceutical Industries’ and the market’s earnings growth lately. One possibility is that the P/E is high…
Read More…
Pinning Down Sun Pharmaceutical Industries Limited’s (NSE:SUNPHARMA) P/E Is Difficult Right Now
